In the treatment of patients with Crohn’s disease refractory to anti-tumour necrosis factor, ustekinumab is superior to vedolizumab in terms of steroid‐free remission and treatment persistence outcomes in both the induction and maintenance phases, as shown in the results of a comparative study.
Insulin-like growth factor 1 (IGF-1) to insulin-like growth factor–binding protein 2 (IGFBP-2) ratio ≤0.85 appears to be a useful biomarker in the diagnosis of pancreatic adenocarcinoma (PDAC), suggests a recent study.
Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
In highly viraemic mothers, initiating treatment with tenofovir alafenamide fumarate (TAF) at the 13th gestational week or later in pregnancy puts a lid on hepatitis B virus (HBV) and prevents vertical transmission when infants receive standard immunoprophylaxis, as shown in a study.
Patients with the coronavirus disease 2019 (COVID-19) have an altered faecal microbiome, characterized by enrichments in opportunistic pathogens, and depletions of beneficial commensals, according to a recent study.
Daily albumin infusion to achieve serum albumin levels of ≥30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.